期刊
CHEMICAL SCIENCE
卷 8, 期 8, 页码 5636-5643出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/c7sc01269a
关键词
-
资金
- Natural Sciences and Engineering Research Council (NSERC) Discovery Grant
- Michael Smith Career Investigator Award
- New Investigator Grant from the Alzheimer's Association [NIRG-15-362537]
- Brain Canada
- Alzheimer's Society of Canada
- Alberta Prion Research Institute (APRI)
- Alzheimer Society of Alberta and Northwest Territories (ASANT)
- Swedish Research Council [350-2012-239]
- ENS Cachan
- Canadian Institutes of Health Research (CIHR)
- APRI
- ASANT
- Tier I CRC
- National Research Foundation of Korea - Korean Government [NRF-2014S1A2A2028270]
- National Institutes of Health [AG048934]
Alzheimer's disease (AD) is a multifactorial disease that is characterized by the formation of intracellular neurofibrillary tangles and extracellular amyloid-beta (A beta) plaque deposits. Increased oxidative stress, metal ion dysregulation, and the formation of toxic A beta peptide oligomers are all considered to contribute to the etiology of AD. In this work we have developed a series of ligands that are multi-target-directed in order to address several disease properties. 2-(1-(3-Hydroxypropyl)-1H-1,2,3-triazol-4-yl) phenol (POH), 2-(1-(2-morpholinoethyl)-1H-1,2,3-triazol-4-yl) phenol (PMorph), and 2-(1-(2-thiomorpholinoethyl)-1H-1,2,3-triazol-4-yl) phenol (PTMorph) have been synthesized and screened for their antioxidant capacity, Cu-binding affinity, interaction with the A beta peptide and modulation of A beta peptide aggregation, and the ability to limit A beta(1-42)-induced neurotoxicity in human neuronal culture. The synthetic protocol and structural variance incorporated via click chemistry, highlights the influence of R-group modification on ligand-A beta interactions and neuroprotective effects. Overall, this study demonstrates that the phenoltriazole ligand scaffold can target multiple factors associated with AD, thus warranting further therapeutic development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据